Assay News and Research

RSS

UMMS researchers commissioned by Alpha-1 Project to develop PiZ antibody

Researchers at the University of Massachusetts Medical School (UMMS) have been commissioned by the Alpha-1 Project (TAP) to develop a PiZ antibody. The antibody will be used to track the presence of mutant alpha-1 PiZ protein in human blood serum, an essential tool in testing potential therapies for Alpha-1 Antitrypsin Deficiency (Alpha-1).

13 Jan 2014

Meridian's TRU FLU assay gets FDA clearance for analytical sensitivity claim for avian Influenza H7N9 strain

Meridian Bioscience, Inc. today announced that the company's TRU FLU assay received FDA clearance for an analytical sensitivity claim for the novel avian Influenza H7N9 strain, A/Anhui/1/2013. TRU FLU is a rapid immunoassay that detects influenza A and influenza B viruses in 15 minutes in human respiratory specimens.

10 Jan 2014

TSRI researchers develop new fluid biopsy technique to identify patients at high risk of heart attack

A new "fluid biopsy" technique that could identify patients at high risk of a heart attack by identifying specific cells as markers in the bloodstream has been developed by a group of researchers at The Scripps Research Institute.

9 Jan 2014

ProteinSimple introduces revolutionary re-invention of Western blot

ProteinSimple today introduced Wes, another revolutionary re-invention of the Western blot. Wes is the bold evolution of the popular Simple Western family of instruments, delivering simplicity and performance like no product before it. With just 30 minutes of sample prep, Wes will analyze up to 25 samples in under 3 hours and he will do it all for less than the price of a high-end Western imager.

From ProteinSimple 8 Jan 2014

Insight Genetics receives $1.5M SBIR contract to research on resistance mutations in NSCLC patients

Insight Genetics, Inc. today announced it has received a new $1.5 million Phase II Small Business Innovation Research contract from the National Cancer Institute.

8 Jan 2014

Biothera reports positive results from Phase 2 clinical trial of Imprime PGG in NSCLC patients

Biothera today reported positive results from its proof of concept Phase 2 clinical trial in 90 patients with advanced non-small cell lung cancer (NSCLC) at the American Association for Cancer Research and the International Association for the Study of Lung Cancer joint conference on the Molecular Origins of Lung Cancer in San Diego.

8 Jan 2014

Horizon, AstraZeneca partner to explore oncology-relevant genotypes to identify novel drug targets

Horizon Discovery and AstraZeneca have entered into a research, collaboration and license agreement to explore a range of oncology-relevant genotypes with the aim of identifying and validating a number of novel drug targets. This deal is the second collaboration between AstraZeneca and Horizon, and follows the announcement in April 2013 of an oncology discovery program to explore Horizon's first-in-class kinase target program, HD-001.

7 Jan 2014

Demand growing for Porvair Sciences' Chromatrap ChIP assay technology

Porvair Sciences reports strong growing demand for their Chromatrap chromatin immunoprecipitation (ChIP) assay technology from academic groups and biopharmaceutical organisations involved with epigenetic research.

From Chromatrap® - Porvair Sciences Ltd 6 Jan 2014

Bioanalytical Systems reports net income of $252,000 for fourth quarter 2013

Bioanalytical Systems, Inc. today announced financial results for the fourth quarter and fiscal 2013, highlighted by net income of $252,000, or $0.03 per diluted share, for the fourth quarter and $773,000, or $0.09 per diluted share, for the year. This compares to net losses of $2,696,000, or $0.36 per share and $6,317,000, or $0.88 per share, for the fourth quarter and fiscal 2012.

24 Dec 2013

Fluidigm announces universal sample prep workflow for single-cell DNA sequencing

Fluidigm Corporation today announced a universal sample prep workflow for single-cell DNA sequencing that runs on its C1TM Single-Cell Auto Prep System. This workflow streamlines targeted, whole exome and whole genome sequencing in heterogeneous cell populations and enables researchers to discover and screen somatic mutations, such as SNP, small indels, and translocations.

24 Dec 2013

LSDF announces research and development grants to commercialize health-related technologies

The Life Sciences Discovery Fund (LSDF) today announced $1.1 million in five Proof of Concept grants to Washington for-profit and non-profit organizations to foster the translation of health-related products from the laboratory into the commercial marketplace.

19 Dec 2013

Aerobic glycolysis is a cause of malignancy, show Berkeley Lab researchers

Metabolism was lost in the shadows of cancer research for decades but has recently been reclaiming some of the spotlight. Now, Mina Bissell, Distinguished Scientist with Berkeley Lab's Life Sciences Division and a leading authority on breast cancer, has shown that aerobic glycolysis - glucose metabolism in the presence of oxygen - is not the consequence of the cancerous activity of malignant cells but is itself a cancerous event.

18 Dec 2013

Octapharma enrolls first patients in GAM-27 Phase II/III clinical trial for relapsing multiple sclerosis

Octapharma AG, one of the largest global manufacturers of human proteins, today announced the enrolment of the first two patients in its GAM-27 Phase II/III clinical trial for the treatment of relapsing multiple sclerosis. Through intravenous administration of immunoglobulin (Octagam 5%), the study seeks to support the overall clinical benefit of a lower annualised relapse rate in patients where first-line treatment is not suitable.

18 Dec 2013

Scientists find vaccine that blocks invasion of blood cell by Malaria parasite

Scientists from Singapore's Nanyang Technological University (NTU) have discovered a key process during the invasion of the blood cell by the Malaria parasite, and more importantly, found a way to block this invasion.

16 Dec 2013

PAM50 FDA-cleared breast cancer test to be launched at ARUP Laboratories

The PAM50 breast cancer signature developed at the University of Utah and Huntsman Cancer Institute received FDA approval and will launch at ARUP Laboratories in Salt Lake City. The test utilizes gene expression data from 50 genes weighted together with clinical variables to generate a risk category and numerical score to assess a patient's risk of distant recurrence at ten years in postmenopausal women with node-negative (Stage I or II) or node-positive (Stage II), Hormone Receptor-Positive (HR+) breast cancer.

16 Dec 2013

NTU researchers find way to block invasion of Malaria parasite in blood cells

Scientists from Singapore's Nanyang Technological University have discovered a key process during the invasion of the blood cell by the Malaria parasite, and more importantly, found a way to block this invasion.

16 Dec 2013

Study shows effectiveness of PAM50-based Prosigna Breast Cancer Prognostic Gene Signature Assay

NanoString Technologies, Inc., a provider of life science tools for translational research and molecular diagnostic products, today announced new results from a combined analysis of the Austrian Breast & Colorectal Cancer Study Group 8 (ABCSG-8) and Trans-Arimidex, Tamoxifen, Alone or in Combination (TransATAC) studies. These results, which evaluated samples from 2,137 patients, suggest that the PAM50-based Prosignaz Breast Cancer Prognostic Gene Signature Assay may help identify women with late distant recurrence after five years of endocrine treatment.

13 Dec 2013

WHO hands over management of world's largest public collection of TB strains to ITM in Antwerp

The World Health Organisation handed over the management of the world's largest public collection of tuberculosis strains to the Institute of Tropical Medicine in Antwerp. These TB-strains play a key role in supporting scientific research into infectious diseases, particularly towards a better understanding of the TB bacterium's drug resistance.

13 Dec 2013

Circulating nucleosomes and colorectal cancer diagnostics: an interview with Dr. Stefan Holdenrieder, University Hospital Bonn

For my MD thesis I modified and evaluated an immunological assay that detected the cell death products “nucleosomes” as a new blood-based cancer biomarker. As cell death processes are enhanced or suppressed during different stages of tumor development, it was assumed that they may enable stage-dependent detection of cancer disease.

12 Dec 2013

New assay allows rapid and sensitive detection of Chlamydia trachomatis

Researchers have developed a new assay for rapid and sensitive detection of Chlamydia trachomatis, the most common sexually transmitted infection (STI) in humans.

12 Dec 2013

Assay News and Research

UMMS researchers commissioned by Alpha-1 Project to develop PiZ antibody

Meridian's TRU FLU assay gets FDA clearance for analytical sensitivity claim for avian Influenza H7N9 strain

TSRI researchers develop new fluid biopsy technique to identify patients at high risk of heart attack

ProteinSimple introduces revolutionary re-invention of Western blot

Insight Genetics receives $1.5M SBIR contract to research on resistance mutations in NSCLC patients

Biothera reports positive results from Phase 2 clinical trial of Imprime PGG in NSCLC patients

Horizon, AstraZeneca partner to explore oncology-relevant genotypes to identify novel drug targets

Demand growing for Porvair Sciences' Chromatrap ChIP assay technology

Bioanalytical Systems reports net income of $252,000 for fourth quarter 2013

Fluidigm announces universal sample prep workflow for single-cell DNA sequencing

LSDF announces research and development grants to commercialize health-related technologies

Aerobic glycolysis is a cause of malignancy, show Berkeley Lab researchers

Octapharma enrolls first patients in GAM-27 Phase II/III clinical trial for relapsing multiple sclerosis

Scientists find vaccine that blocks invasion of blood cell by Malaria parasite

PAM50 FDA-cleared breast cancer test to be launched at ARUP Laboratories

NTU researchers find way to block invasion of Malaria parasite in blood cells

Study shows effectiveness of PAM50-based Prosigna Breast Cancer Prognostic Gene Signature Assay

WHO hands over management of world's largest public collection of TB strains to ITM in Antwerp

Circulating nucleosomes and colorectal cancer diagnostics: an interview with Dr. Stefan Holdenrieder, University Hospital Bonn

New assay allows rapid and sensitive detection of Chlamydia trachomatis

Exploring Strategies for Targeting Kinases in Innate Immunity eBook

How Omics Technologies Are Transforming Biological Research and Drug Discovery

How microplastics and bacteria interact to drive antibiotic resistance

Single-cell proteomics: Revealing proteome diversity from cellular heterogeneity to non-canonical biology

Latest News